Continuous subcutaneous insulin infusion in diabetes: Patient populations, safety, efficacy, and pharmacoeconomics

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 1, 2016, Pages 21-39

  Pozzilli, Paolo ^a   Battelino, Tadej ^b,c   Danne, Thomas ^d   Hovorka, Roman ^e   Jarosz Chobot, Przemyslawa ^f   Renard, Eric ^g  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d Diabetes Centre for Children and Adolescents   (Germany)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Continuous subcutaneous insulin infusion; Diabetes mellitus; Paediatric; Pharmacoeconomics; Pregnancy; Rapid acting insulin analogue

Indexed keywords

INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN DERIVATIVE; SHORT ACTING INSULIN;

ARTIFICIAL PANCREAS; CLOSED LOOP SYSTEM; CONTINUOUS GLUCOSE MONITOR; CONTINUOUS INFUSION; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EUROPE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN PUMP; META ANALYSIS (TOPIC); MONITOR; OCCLUSION; PATIENT SATISFACTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; AMBULATORY MONITORING; ANALYSIS; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPUTER SECURITY; DIABETES MELLITUS, TYPE 1; ECONOMICS; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HYPERGLYCEMIA; PERSONALIZED MEDICINE; SUBCUTANEOUS DRUG ADMINISTRATION; TRENDS;

BLOOD GLUCOSE; COMPUTER SECURITY; DIABETES MELLITUS, TYPE 1; EUROPE; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN INFUSION SYSTEMS; INSULIN, SHORT-ACTING; INSULINS; MONITORING, AMBULATORY; PRECISION MEDICINE; QUALITY OF LIFE;

EID: 84953837663     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2653     Document Type: Review

References (140)

1. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
2. DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376.
3. Anonymous, the Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Anonymous, the UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. Cummins E, Royle P, Snaith A, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14: iii-iv xi-xvi, 1-181.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
7. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; 1 CD005103. doi:10.1002/14651858.CD005103.pub2.
8. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med 2012; 366: 1616-1624.
9. Thabit H, Hovorka R. Closed-loop insulin delivery in type 1 diabetes. Endocrinol Metab Clin North Am 2012; 41: 105-117.
10. Bergenstal RM, Tamborlane WV, Ahmann A, et al. STAR 3 study group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363: 311-320.
11. Bode B, Weinstein R, Bell D, et al. Comparison of insulin Aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002; 25: 439-444.
12. Phillip M, Battelino T, Rodriguez H, et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007; 30: 1653-1662.
13. Bergholtz CH, Olsen B, Johannesen J. Insulin pump therapy in children and teenagers. Ugeskr Laeger 2009; 171: 1913-1918[Article in Danish].
14. Renard E. Insulin pump use in Europe. Diabetes Technol Ther 2010; 12(Suppl 1): S29-S32.
15. Sulmont V, Lassmann-Vague V, Guerci B, et al. French pediatric PUMP group. Access of children and adolescents with type 1 diabetes to insulin pump therapy has greatly increased in France since 2001. Diabetes Metab 2011; 37: 59-63.
16. Pickup J. Insulin pumps. Int J Clin Pract Suppl 2011; (170): 16-19.
17. Pickup JD. The evidence base for diabetes technology: appropriate and inappropriate meta-analysis. J Diabetes Sci Technol 2013; 7: 1567-1574.
18. Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009; 94: 729-740.
19. Golden SH, Brown T, Yeh HC, et al. Methods for insulin delivery and glucose monitoring: comparative effectiveness. Comparative Effectiveness Review No. 57. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2007-10061-I.) AHRQ Publication No. 12-EHC036-EF. Rockville, MD: Agency for Healthcare Research and Quality 2012. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047870/. Accessed May 16, 2014.
20. Medical Advisory Secretariat. Continuous subcutaneous insulin infusion pumps for type 1 and type 2 adult diabetic populations: an evidence-based analysis. Ontario Health Technology Assessment 2009; Series 9(20).
21. Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51: 941-951.
22. Johnson SL, McEwen LN, Newton CA, et al. The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes. J Diabetes Complications 2011; 25: 211-215.
23. Berthe E, Lireux B, Coffin C, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res 2007; 39: 224-229.
24. Bode BW. Insulin pump use in type 2 diabetes. Diabetes Technol Ther 2010; 12(Suppl 1): S17-S21.
25. Reznik Y, Cohen O, Aronson R, et al. OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014; 384: 1265-1272.
26. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324(7339): 705.
27. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004; 8: iii 1-171.
28. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-774.
29. Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: Importance of blood glucose variability. Diabetes Metab Res Rev 2006; 22: 232-237.
30. Retnakaran R, Hochman J, DeVries JH, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27: 2590-2596.
31. Jacobsen IB, Henriksen JE, Hother-Nielsen O, Vach W, Beck-Nielsen H. Evidence-based insulin treatment in type 1 diabetes mellitus. Diabetes Res Clin Pract 2009; 86: 1-10.
32. National Institute for Health and Care Excellence. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus, TA151, 2008. Available at: http://guidance.nice.org.uk/TA151/Guidance/pdf/English. Accessed May 16, 2014.
33. Lassmann-Vague V, Clavel S, Guerci B, et al. Société francophone du diabète (ex ALFEDIAM). When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009. Diabetes Metab 2010; 36: 79-85.
34. International Diabetes Federation/International Society for Pediatric and Adolescent Diabetes. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence 2014. Available at: http://www.ispad.org/resource-type/idfispad-2011-global-guideline-diabetes-childhood-and-adolescence. Accessed April 14, 2014.
35. National Institute for Health and Care Excellence. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (CG63) 2008. Available at: http://www.nice.org.uk/guidance/index.jsp?action=download&o=41320. Accessed May 16, 2014.
36. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003; 20: 863-866.
37. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006; 2 CD003287.
38. Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr Pract 2011; 17: 271-280.
39. van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 2011; 13: 607-614.
40. Kerr D, Wizemann E, Senstius J, Zacho M, Ampudia-Blasco FJ. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review. J Diabetes Sci Technol 2013; 7: 1595-1606.
41. Di Bartolo P, Pellicano F, Scaramuzza A, et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther 2008; 10: 495-498.
42. Tamborlane WV, Renard E, Wadwa RP, et al. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart. J Diabetes 2014. DOI: 10.1111/1753-0407.12162. [Epub ahead of print].
43. Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia 2013; 56: 2392-2400.
44. Dovc K, Telic SS, Lusa L, et al. Improved metabolic control in pediatric patients with type 1 diabetes: a nationwide prospective 12-year time trends analysis. Diabetes Technol Ther 2014; 16: 33-40.
45. Sulmont V, Souchon PF, Gouillard-Darnaud C, et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment? J Pediatr 2010; 157: 103-107.
46. Cooper MN, O'Connell SM, Davis EA, Jones TW. A population-based study of risk factors for severe hypoglycaemia in a contemporary cohort of childhood-onset type 1 diabetes. Diabetologia 2013; 56: 2164-2170.
47. Tubiana-Rufi N. Insulin pump therapy in neonatal diabetes. Endocr Dev 2007; 12: 67-74.
48. Beardsall K, Pesterfield CL, Acerini CL. Neonatal diabetes and insulin pump therapy. Arch Dis Child Fetal Neonatal Ed 2011; 96: F223-F224.
49. Mianowska B, Szadkowska A, Fendler W, Mlynarski W. Use of lispro insulin diluted with normal saline to 10 U/ml in an insulin pump: case report. J Diabetes Sci Technol 2012; 6: 1238-1239.
50. Seereiner S, Neeser K, Weber C, et al. Attitudes towards insulin pump therapy among adolescents and young people. Diabetes Technol Ther 2010; 12: 89-94.
51. Olinder AL, Nyhlin KT, Smide B. Reasons for missed meal-time insulin boluses from the perspective of adolescents using insulin pumps: 'lost focus'. Pediatr Diabetes 2011; 12(4 Pt 2): 402-409.
52. O'Connell MA, Donath S, Cameron FJ. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes 2011; 12: 556-559.
53. Moreau F, Spizzo H, Bursztejn C, et al. Factitious self-manipulation of the external insulin pump in adolescents with Type 1 diabetes. Diabet Med 2011; 28: 623-624.
54. Burdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004; 113: e221-e224.
55. Diabetes Research in Children Network (DirecNet) Study Group, Tsalikian E, Kollman C, et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care 2006; 29: 2200-2204.
56. Admon G, Weinstein Y, Falk B, et al. Exercise with and without an insulin pump among children and adolescents with type 1 diabetes mellitus. Pediatrics 2005; 116: e348-e355.
57. Delvecchio M, Zecchino C, Salzano G, et al. Effects of moderate-severe exercise on blood glucose in Type 1 diabetic adolescents treated with insulin pump or glargine insulin. Endocrinol Invest 2009; 32: 519-524.
58. Low KG, Massa L, Lehman D, Olshan JS. Insulin pump use in young adolescents with type 1 diabetes: a descriptive study. Pediatr Diabetes 2005; 6: 22-31.
59. Yardley JE, Iscoe KE, Sigal RJ, Kenny GP, Perkins BA, Riddell MC. Insulin pump therapy is associated with less post-exercise hyperglycemia than multiple daily injections: an observational study of physically active type 1 diabetes patients. Diabetes Technol Ther 2013; 15: 84-88.
60. Churchill JN, Ruppe RL, Smaldone A. Use of continuous insulin infusion pumps in young children with type 1 diabetes: a systematic review. J Pediatr Health Care 2009; 23: 173-179.
61. Pańkowska E, Błazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009; 10: 52-58.
62. Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006; 117: 2126-2131.
63. Tubiana-Rufi N, Coutant R, Bloch J, et al. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. Horm Res 2004; 62: 265-271.
64. Weinzimer SA, Ternand C, Howard C, et al. Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008; 31: 210-215.
65. Apidra SmPC 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000557/human_med_000648.jsp&mid=WC0b01ac058001d124. Accessed May 16, 2014.
66. NovoRapid SmPC 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000258/human_med_000935.jsp&mid=WC0b01ac058001d124. Accessed May 16, 2014.
67. Humalog SmPC 2011. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000088/human_med_000820.jsp&mid=WC0b01ac058001d124. Accessed May 16, 2014.
68. Kaiserman K, Rodriguez H, Stephenson A, Wolka L, Fahrbach JL. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus. Endocr Pract 2012; 18: 418-424.
69. Beck RW, Tamborlane WV, Bergenstal RM, et al. T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012; 97: 4383-4389.
70. Holterhus PM, Bokelmann J, Riepe F, et al. German/Austrian DPV-Initiative and the German Pediatric CSII Working Group. Predicting the optimal basal insulin infusion pattern in children and adolescents on insulin pumps. Diabetes Care 2013; 36: 1507-1511.
71. Bratina N, Battelino T. Insulin pumps and continuous glucose monitoring (CGM) in preschool and school-age children: how schools can integrate technology. Pediatr Endocrinol Rev 2010; 7(Suppl 3): 417-421.
72. Bergenstal RM, Klonoff DC, Garg SK, et al. ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-232.
73. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013; 310: 1240-1247.
74. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368: 824-833.
75. Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. J Manag Care Pharm 2012; 18(6 Suppl): S1-S17.
76. Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007; 3 CD005542.
77. Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: A systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197: 447-456.
78. Kallas-Koeman MM, Kong JM, Klinke JA, et al. Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes. Diabetologia 2014; 57: 681-689.
79. Durnwald CP, Landon MB. Insulin analogues in the management of the pregnancy complicated by diabetes mellitus. Curr Diab Rep 2011; 11: 28-34.
80. Edson EJ, Bracco OL, Vambergue A, Koivisto V. Managing diabetes during pregnancy with insulin lispro: a safe alternative to human insulin. Endocr Pract 2010; 16: 1020-1027.
81. García-Domínguez M, Herranz L, Hillman N, et al. Use of insulin lispro during pregnancy in women with pregestational diabetes mellitus. Med Clin(Barc) 2011; 137: 581-586.
82. Chico A, Saigi I, García-Patterson A, et al. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin. Diabetes Technol Ther 2010; 12: 937-945.
83. González Blanco C, Chyico Ballesteros A, Gich Saladich I, Corcoy Pla R. Glycemic control and pregnancy outcomes in women with type 1 diabetes mellitus using lispro versus regular insulin: a systematic review and meta-analysis. Diabetes Technol Ther 2011; 13: 907-911.
84. Luijf YM, Arnolds S, Avogaro A, et al. On behalf of the Ap@home consortium. Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time. Diabetes Technol Ther 2013; 15: 575-579.
85. Schmid V, Hohberg C, Borchert M, Forst T, Pfützner A. Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3. J Diabetes Sci Technol 2010; 4: 976-982.
86. Thethi TK, Rao A, Kawji H, et al. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications 2010; 24: 73-78.
87. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol 2008; 2: 450-455.
88. Zisser H. Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care 2008; 31: 238-239.
89. Realsen J, Goettle H, Chase HP. Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. Diabetes Technol Ther 2012; 14: 1149-1154.
90. Zisser HC, Bevier W, Dassau E, Jovanovic L. Siphon effects on continuous subcutaneous insulin infusion pump delivery performance. J Diabetes Sci Technol 2010; 4: 98-10385.
91. King BR, Goss PW, Paterson MA, Crock PA, Anderson DG. Changes in altitude cause unintended insulin delivery from insulin pumps: mechanisms and implications. Diabetes Care 2011; 34: 1932-1933.
92. Guilhem I, Balkau B, Lecordier F, et al. Insulin pump failures are still frequent: a prospective study over 6 years from 2001 to 2007. Diabetologia 2009; 52: 2662-2664.
93. Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol 2012; 6: 954-964.
94. Riveline JP, Jollois FX, Messaoudi N, et al. Groupe Pompe Sud-Francilien Insulin-pump use in everyday practice: data from an exhaustive regional registry in France. Diabetes Metab 2008; 34: 132-139.
95. Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr 2008; 152: 622-628.
96. Renard E, Guerci B, Leguerrier AM, Boizel R, Accu-Chek FlexLink Study Group. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Diabetes Technol Ther 2010; 12: 769-773.
97. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4: 661-667.
98. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013; 39: 445-453.
99. Thabit H. Insulin pump therapy in type 1 diabetes-merging technology with diabetes care. Am Med J 2012; 3: 93-99.
100. Medtronic Minimed Inc 2013. Safety first. Available at: http://www.medtronic-diabetes.co.uk/product-information/infusion-sets/safety-first.html. Accessed May 16, 2014.
101. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab Res Rev 2009; Rev 25: 99-111.
102. Woods RJ, Alarcón J, McVey E, Pettis RJ. Intrinsic fibrillation of fast-acting insulin analogs. J Diabetes Sci Technol 2012; 6: 265-276.
103. Jovanovič L. Letter written in response to van bon et al. "Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial". Diabetes Technol Ther 2011; 13: 869-870.
104. Rubin RR, Peyrot M, STAR 3 Study Group. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. Diabetes Technol Ther 2012; 14: 143-151.
105. Frøisland DH, Graue M, Markestad T, Skrivarhaug T, Wentzel-Larsen T, Dahl-Jørgensen K. Health related quality of life among Norwegian children and adolescents with type 1 diabetes on intensive insulin treatment: a population based study. Acta Paediatr 2013; 102: 889-895.
106. Lozano-Serrano M, García-Seco JA, García-Seco F, et al. Satisfaction and quality of life evaluation in patients with type 1 diabetes mellitus treated using continuous subcutaneous insulin infusion compared with multiple daily injections. Enferm Clin 2013; 23: 96-102[Article in Spanish].
107. Matziou V, Tsoumakas K, Vlahioti E, et al. Factors influencing the quality of life of young patients with diabetes. J Diabetes 2011; 3: 82-90.
108. Cherubini V, Gesuita R, Bonfanti R, et al., VIPKIDS Study Group. Health-related quality of life and treatment preferences in adolescents with type 1 diabetes. The VIPKIDS study. Acta Diabetol 2014; 51: 43-51.
109. Rubin RR, Peyrot M, Chen X, Frias JP. Patient-reported outcomes from a 16-week open-label, multicenter study of insulin pump therapy in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2010; 12: 901-906.
110. Marmolin ES, Brødsgaard J, Gjessing HJ, et al. Better treatment of outpatients with type 1 diabetes after introduction of continuous subcutaneous insulin infusion. Dan Med J 2012; 59: A4445.
111. Lukács A, Kiss-Tóth E, Varga B, Soós A, Takác P, Barkai L. Benefits of continuous subcutaneous insulin infusion on quality of life. Int J Technol Assess Health Care 2013; 29: 48-52.
112. Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes 2008; 9: 472-479.
113. Kordonouri O, Pankowska E, Rami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010; 53: 2487-2495.
114. Sharrow SD, Glass LC, Dobbins MA. 14-day in vitro chemical stability of insulin lispro in the MiniMed paradigm pump. Diabetes Technol Ther 2012; 14: 264-270.
115. Weiss RC, van Amerongen D, Bazalo G, Aagren M, Bouchard JR. Economic benefits of improved insulin stability in insulin pumps. Manag Care 2011; 20: 42-47.
116. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet Med 2005; 22: 1239-1245.
117. Nørgaard K, Sohlberg A, Goodall G. Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes. Ugeskr Laeger 2010; 172: 2020-2025[Article in Danish].
118. Bolli GB, Kerr D, Thomas R, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009; 32: 1170-1176.
119. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011; 7: 385-395.
120. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 2013; 36: 1851-1858.
121. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2013; 15: 91-99.
122. Heller A, Feldman B. Electrochemical glucose sensors and their applications in diabetes management. Chem Rev 2008; 108: 2482-2505.
123. Renard E. Implantable continuous glucose sensors. Curr Diabetes Rev 2008; 4: 169-174.
124. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805.
125. Zisser H, Robinson L, Bevier W, et al. Bolus calculator: a review of four "smart" insulin pumps. Diabetes Technol Ther 2008; 10: 441-444.
126. Garg S, Brazg RL, Bailey TS, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther 2012; 14: 205-209.
127. Buckingham B, Chase HP, Dassau E, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010; 33: 1013-1017.
128. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008; 31: 934-939.
129. Renard E, Cobelli C, Kovatchev BP. Closed loop developments to improve glucose control at home. Diabetes Res Clin Pract 2013; 102: 79-85.
130. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342: d1855.
131. Breton M, Farret A, Bruttomesso D, et al. International Artificial Pancreas Study Group. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012; 61: 2230-2237.
132. Patek SD, Magni L, Dassau E, et al. International artificial pancreas (iAP) study group. Modular closed-loop control of diabetes. IEEE Trans Biomed Eng 2012; 59: 2986-2999.
133. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375: 743-751.
134. Dauber A, Corcia L, Safer J, Agus MS, Einis S, Steil GM. Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial. Diabetes Care 2013; 36: 222-227.
135. Murphy HR, Elleri D, Allen JM, et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 2011; 34: 406-411.
136. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010; 2 27ra27.
137. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012; 35: 2148-2155.
138. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013; 185: 297-305.
139. Frenger P. Hacking medical devices a review - biomed 2013. Biomed Sci Instrum 2013; 49: 40-47.
140. Hammond P, Liebl A, Grunder S. International survey of insulin pump users: impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life. Prim Care Diabetes 2007; 1: 143-146.